Cambridge Healthtech Institute’s 4th Annual

Combination Immunotherapy

Distinguishing Promising Cancer Immunotherapy Combinations from the Crowd

20-21 March 2019

 

Treating cancer patients with an immunological combination is an essential strategy that is still growing in popularity. With so many trials ongoing though, it can all get a bit confusing. Whether double immunotherapy combinations or immune checkpoint inhibitors combined with conventional cancer therapy, there are many factors that may influence therapeutic success. Predictive biomarkers, novel antigens, therapeutic mechanism, reducing toxicity and the immune response are all important considerations. This and more will be discussed in at the Combination Immunotherapy conference.

 

Coverage will include, but is not limited to:

 

  • Immune Checkpoint Inhibitor Combinations
  • Bispecific Antibody Combinations
  • Cancer Vaccines and Adjuvant Therapy
  • Conventional Cancer Therapy Combinations
  • Tumour Microenvironment
  • Novel Targets and Biomarkers

 

If you would like to submit a proposal to give a presentation at this meeting, please click here.

 

The deadline for priority consideration is 10 September 2018.

 

All proposals are subject to review by session chairmen and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

 

For more details on the conference, please contact:
Joel Hornby, BSc Hons

Conference Director

Cambridge Healthtech Institute

Phone: (+1) 781 247 1816
Email: jhornby@healthtech.com

 

For partnering and sponsorship information, please contact:

Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286
Email: reymael@healthtech.com